PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to develop and commercialize four of Arrowhead’s investigational…
RAHWAY, N.J. & RALEIGH, N.C.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today…
Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share…
A legacy defined by innovation, leadership, and humanity. We are extremely saddened to share that our Managing Partner, Jack B. Nielsen, passed away on June 5th, 2025, after a courageous year-long battle with cancer. Jack…
BOSTON–(BUSINESS WIRE)–May 8, 2025– Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has approved AVMAPKI™…
Palo Alto, May 7th, 2025: Vivo Capital (“Vivo” or “the Firm”), a leading global investment firm focused exclusively on healthcare and life sciences, has closed the third cycle of its Vivo Opportunity Fund and its…
CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the U.S. Food and Drug Administration (FDA) has approved ZEVASKYN™ (pronounced as ‘ZEE-vah-skin’) (prademagene zamikeracel) gene-modified cellular sheets, also known as…
PALO ALTO, Calif.–(BUSINESS WIRE)–Vivo Capital (“Vivo” or the “Firm”), a leading global investment firm focused exclusively on healthcare and life sciences, today announced multiple legal proceedings to challenge the irresponsible actions taken by the current…
March 26 (Reuters) – The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics’ (SLNO.O), opens new tab drug to treat a rare genetic disorder, making it the first treatment available for patients who…
March 21st, 2025, Hong Kong, China – VISEN Pharmaceuticals (Stock Code: 2561.HK), an innovative biopharmaceutical company focused on endocrine diseases, today announces the allotment results of the global offering (the “Global Offering”). The Offer Price…